June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Trifocal intraocular lens Acrysof IQ Panoptix: visual performance and quality of life at 6 months
Author Affiliations & Notes
  • Clément GRATIOT
    78150, Centre Hospitalie de Versailles, Le Chesnay, France
  • Heloise TORRES
    78150, Centre Hospitalie de Versailles, Le Chesnay, France
  • Raphaëlle BOULHOL
    78150, Centre Hospitalie de Versailles, Le Chesnay, France
  • Laurence LE GROS
    78150, Centre Hospitalie de Versailles, Le Chesnay, France
  • Marie-Laure PASCAL
    78150, Centre Hospitalie de Versailles, Le Chesnay, France
  • Edouard Koch
    78150, Centre Hospitalie de Versailles, Le Chesnay, France
  • Footnotes
    Commercial Relationships   Clément GRATIOT, None; Heloise TORRES, None; Raphaëlle BOULHOL, None; Laurence LE GROS, None; Marie-Laure PASCAL, None; Edouard Koch, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1689. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Clément GRATIOT, Heloise TORRES, Raphaëlle BOULHOL, Laurence LE GROS, Marie-Laure PASCAL, Edouard Koch; Trifocal intraocular lens Acrysof IQ Panoptix: visual performance and quality of life at 6 months. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1689.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Since 2010, trifocal intraocular lenses (IOL) are available to correct the intermediate vision in addition of the distance and near visions in order to face up the development of screen activities. AcrySof IQ PanOptix therefore proposes three foci including one for the intermediate vision at 60 cm. The purpose of this study was to evaluate the visual performance and the quality of life of patients implanted with this intraocular lens.

Methods : Our study had a retrospective observational monocentric design including 17 patients (34 eyes) bilaterally implanted with the trifocal IOL PanOptix. At least 6 months after the surgery, we assessed for both eyes: the best uncorrected distance visual acuity (UDVA), intermediate visual acuity (UIVA) and near visual acuity (UNVA). A quality of life VF-14 questionnaire and a satisfaction questionnaire were then filled out by patients.

Results : 17 patients (34 eyes) were included, mean age was 76 years old (+/-10), for a median follow-up of 12 months (+/-6.5). Post-operative results were: median UDVA: 0.05 LogMAR (+/-0.14), UIVA: 0.53 LogMAR (+/-0.16), UNVA: 0.14 LogMAR (+/-0.8). 83% of the patients (n=14) did not use glasses after the surgery. The mean wearing time of glasses for these 17% was 6 minutes per day. 76% of the patients declared themselves “Very satisfied” and 24% “Rather satisfied”. The mean VF-14 score was 94.8/100 (+/-6.8). Main side-effects self-reported by patients were: halos: 35%, photophobia: 65%, discomfort for driving at night: 23%, visual fatigue: 23%, need more light while reading: 58%.

Conclusions : Refractive results of the AcrySof IQ PanOptix IOL in our study were similar to those we found in the literature. Side effects were more common but the shorter follow-up may explain this observation. The spectacle dependence for 17% of the patients was still low regarding the wearing time of glasses during the day that was of 6 minutes.
In our study, the AcrySof IQ PanOptix IOL demonstrated satisfying refractive results with an important spectacle independence and a wearing time of glasses shorter than 1% of waking time. Despite high rates of side effects, those did not led to dissatisfaction thanks to a good preoperative information of the patient.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×